Trump announces trade deal with EU following months of negotiations
Rachna Khosla, Senior Vice President of Business Development at Amgen Inc . (NASDAQ:AMGN), a prominent biotechnology company with a market capitalization of $156.45 billion and a robust "Good" financial health score according to InvestingPro, recently sold 1,500 shares of the company’s common stock. The shares were sold at an average price of $289.68, totaling approximately $434,520. Following this transaction, Khosla retains 8,162 shares, which include 112 Dividend Equivalents granted under Amgen’s equity incentive plan. These equivalents are subject to a dividend reinvestment plan, converting into shares of common stock according to the vesting schedule. Notably, Amgen has maintained and raised its dividend for 14 consecutive years, currently offering a 3.28% yield. For comprehensive insider trading analysis and additional insights, InvestingPro subscribers can access detailed reports covering 1,400+ US stocks, including Amgen’s complete financial health metrics and Fair Value assessment.
In other recent news, Amgen has made several significant announcements impacting its investors. The company held its Annual Meeting, where shareholders approved the election of 12 directors and ratified Ernst & Young LLP as the independent accountants for 2025. Shareholders also supported the executive compensation plan, indicating strong backing for the company’s leadership. Additionally, Piper Sandler adjusted its price target for Amgen to $328, maintaining an Overweight rating, citing increased research and development spending. Meanwhile, Erste Group downgraded Amgen’s stock from Buy to Hold, reflecting concerns about a potential slowdown in revenue and profit growth in the coming years. S&P Global Ratings revised Amgen’s outlook from negative to stable, recognizing the company’s efforts in debt reduction and maintaining a solid cash flow. Despite patent expirations, Amgen continues to see growth in products like Repatha, Tezspire, and Blincyto, alongside new launches like Imdelltra. The company also faces a dispute with the IRS regarding a transfer pricing matter, which may affect its financial standing in the future. These developments provide a comprehensive view of Amgen’s current financial and strategic positioning.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.